Test Entry - Detail

Detection of Somatic Variants in the IDH1 and IDH2 Genes


General
  Clinical Use: The presence of IDH1&2 exon 4 variants is used as a prognostic marker in grade II and III gliomas and predicts better survival. Assessment of IDH1&2 status is part of the WHO classification scheme for subtyping gliomas and is a useful diagnostic tool to differentiate between malignant (glioma) and benign (reactive gliosis) proliferations of glial cells. IDH mutations are also found in some myeloid malignancies, angioimmunoblastic T-cell lymphomas and some soft tissue tumours such as chondrosarcoma. The mutation hotspots are exon 4, codon 132 of IDH1 and exon 4, codon 172 for IDH2.
Medicare rebate can be applied once per patient lifetime and if IDH1 p.R132H negative has been demonstrated by immunohistochemistry.
  Availability: Samples are tested routinely during the testing laboratory's hours of operation.
Please contact testing laboratory for urgent requests.
  Aliases/Synonyms: Isocitrate Dehydrogenase Gene,  
  Code: HST
  Handling Instructions (to laboratory): Contact testing laboratory for specific transport instructions.
  Hyperlink:
  Reference Interval:
Not Applicable


Collection Requirements
  Container: Sterile Container (STERILE),  
  Sample Type: Fresh/Frozen/Fixed Tissue; Cytology Preparations; Bone Marrow
  Minimum Collection Volume: N/A
  Collection Instructions: Contact testing laboratory for specific collection instructions.


Processing Requirements
  Alternate Containers:
  Processing Instructions:
  Minimum Assay Volume: N/A
  Stability: Dependent on sample type
  Transport Instructions (to testing laboratory): Contact testing laboratory for specific transport instructions.


Testing Locations
  Performed at:
Section Department Site Contact Phone
Molecular Pathology Anatomical Pathology QEII Medical Centre 6457 2679


Last Updated : 05-10-2020 13:44